论文部分内容阅读
目的:检测TMEFF1(tomoregulin-1)在卵巢上皮性浆液性肿瘤中的表达,探讨其临床意义。方法:采用免疫组化SP法检测卵巢上皮性浆液性囊腺癌、卵巢上皮性交界性肿瘤、卵巢上皮性良性肿瘤以及正常卵巢组织中TMEFF1的表达情况,分析其与卵巢上皮性浆液性囊腺癌临床病理参数及预后的关系。结果:TMEFF1以胞膜着色为主,亦有胞浆着色。TMEFF1在卵巢上皮性浆液性囊腺癌中的表达率(90.24%)明显高于卵巢上皮性交界性肿瘤(45.45%)、卵巢上皮性良性肿瘤(33.33%)及正常卵巢(26.67%)(P均<0.05)。在卵巢上皮性浆液性囊腺癌中,TMEFF1表达随FIGO分期增加而逐渐增加(P<0.05),TMEFF1为影响卵巢上皮性浆液性癌预后的独立危险因素(P<0.05)。结论:TMEFF1的表达与卵巢癌的发生、发展及预后相关。
Objective: To investigate the expression of TMEFF1 (tomoregulin-1) in ovarian epithelial serous tumors and to explore its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of TMEFF1 in ovarian epithelial serous cystadenocarcinoma, ovarian epithelial borderline tumor, benign epithelial ovarian tumor and normal ovarian tissue. The expression of TMEFF1 in ovarian epithelial serous cystadenocarcinoma, Relationship between clinicopathological parameters and prognosis of cancer. Results: TMEFF1 mainly membrane staining, but also the cytoplasm coloring. The positive expression rate of TMEFF1 in ovarian epithelial serous cystadenocarcinoma (90.24%) was significantly higher than that in ovarian epithelial borderline tumor (45.45%), benign epithelial ovarian tumor (33.33%) and normal ovary (26.67%) All <0.05). In ovarian epithelial serous cystadenocarcinoma, the expression of TMEFF1 increased gradually with the increase of FIGO staging (P <0.05). TMEFF1 was an independent risk factor affecting the prognosis of ovarian epithelial serous carcinoma (P <0.05). Conclusion: The expression of TMEFF1 is correlated with the occurrence, development and prognosis of ovarian cancer.